April 24, 2025
| Today’s news and insights for biopharma leaders
The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it’ll have for the rest of the year and beyond.
|
Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily beating Wall Street expectations.
|
The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical tariffs given their “speculative” nature, its CFO told analysts.
|
The arrival of vaccine skeptic Robert F. Kennedy Jr. as U.S. health secretary threatens to upend vaccination policy in the country, just as a measles outbreak takes root. Explore what the future holds for the market in
|
The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene beforehand with a targeted medication.
|
The young biotech, sprung out of a Versant incubator in Switzerland, has a pair of antibody drugs it claims to have the potential to treat multiple autoimmune conditions.
|
|
Without in-house expertise, navigating the complexities of radiopharmaceutical trials can be overwhelming. Examine the roadmap from clinical development to commercialization in this playbook.
|
|
From Our Library
Trendline
Supported by Phil Inc
|
Playbook
Custom content for Salesforce & Cognizant
|
Playbook
Custom content for Premier Research
|
Playbook
Custom content for Cardinal Health
|
View all resources
| 
